Vedanta Biosciences
PrivateLast Round
Early Funding
Aug 6, 2026
Total Funding Raised
$317.5M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Vedanta Biosciences is a biotechnology company that develops microbiome-based oral therapies for the treatment of immune-mediated and infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vedanta Biosciences Comparables
Compare Vedanta Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Seres Therapeutics Inc | 81% | |
| MarvelBiome Inc. | 81% | |
| EnteroBiotix | 80% |
Vedanta Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Aug 6, 2026 | ||||
| Grant | Apr 30, 2024 | ||||
| VC Round | Apr 25, 2023 | ||||
| Series D | Jul 21, 2021 | ||||
| Grant | Sep 30, 2020 | ||||
Grant | Dec 5, 2019 |
Vedanta Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Investment | Series C Extension, Series C |
| AMR Action Fund | VC Round, Early Funding |
| SymBiosis Capital Management | Series D, Series C Extension, Series C |
| Invesco Ltd. | Series C, Series B |
| Administration for Strategic Preparedness and Response | Grant |
| Salica Investments | VC Round |
| Korea Investment Partners | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 6, 2026
$40M round led by BNP Paribas Asset Management and AMR Action Fund.
- Apr 1, 2026
Lead asset VE303 enters Phase 3 trial for C. difficile infection.
Vedanta Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Vedanta Biosciences's valuation, stock price, and market status.
Is Vedanta Biosciences a public or private company?
Vedanta Biosciences is a private company.
What is the current stock price of Vedanta Biosciences?
Vedanta Biosciences is a private company, so its shares have no public market price. Caplight tracks Vedanta Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vedanta Biosciences worth (valuation)?
Valuation information for Vedanta Biosciences is not publicly available.
Can I buy Vedanta Biosciences stock?
Vedanta Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vedanta Biosciences's last funding round?
Vedanta Biosciences's most recent funding round was Early Funding on August 6, 2026.
Who are the main investors in Vedanta Biosciences?
Key investors in Vedanta Biosciences include AMR Action Fund, OppenheimerFunds, Magnetar Capital, AXA IM Alts, The Bill & Melinda Gates Foundation Trust.
Will Vedanta Biosciences IPO soon?
No public IPO plans have been announced for Vedanta Biosciences.
How can I track Vedanta Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Vedanta Biosciences's shares on secondary markets.